title: Monoclonal antibody therapeutics and risk for infection.
authors.affiliation: National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
authors.forename: Juan C
authors.initials: JC
authors.lastname: Gea-Banacloche
authors.forename: Geoffrey A
authors.initials: GA
authors.lastname: Weinberg
mesh_terms: D000074323:Alemtuzumab; D000818:Animals; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000009:adverse effects / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D007165:Immunosuppression Therapy; D007239:Infections / Q000209:etiology*; D008214:Lymphocytes / Q000276:immunology / Q000502:physiology; D051379:Mice; D000069442:Natalizumab; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000970:Antineoplastic Agents; D000069442:Natalizumab; D014409:Tumor Necrosis Factor-alpha; D000074323:Alemtuzumab